5-Ethenyl-4-methyl-2-pyrimidinamine | 937014-02-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-Ethenyl-4-methyl-2-pyrimidinamine
• 英文别名: 5-ethenyl-4-methylpyrimidin-2-amine
• CAS: 937014-02-3
• 化学式: C₇H₉N₃
• 分子量: 135.17
• InChiKey: FFEYPAMCSIPRHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE<br/>[FR] BENZOXAZÉPINES EN TANT QU'INHIBITEURS DE PI3K/MTOR ET PROCÉDÉS DE LEURS UTILISATION ET FABRICATION
  申请人：EXELIXIS INC

  公开号：WO2012071519A1

  公开（公告）日：2012-05-31

  The invention is directed 10 Compound's of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.

  该发明涉及公式I的化合物10以及其药用可接受的盐或溶剂化合物，以及制备和使用这些化合物的方法。
• [EN] BENZOXAZEPINES AS INHIBITORS OF MTOR AND METHODS OF THEIR USE AND MANUFACTURE<br/>[FR] BENZOXAZÉPINES EN TANT QU'INHIBITEURS DE MTOR ET PROCÉDÉS DE LEURS UTILISATION ET FABRICATION
  申请人：EXELIXIS INC

  公开号：WO2012071511A1

  公开（公告）日：2012-05-31

  The invention is directed to inhibitors of mTOR and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them. The inhibitors are generally of structural Formula (I) wherein the variables are as defined herein.

  该发明涉及mTOR的抑制剂及其药用盐或溶剂化合物，以及使用它们的方法。这些抑制剂通常具有结构式（I），其中变量如本文所定义。
• Six membered heteroaromatic inhibitors targeting resistant kinase mutations
  申请人：Noronha Glenn

  公开号：US20070149508A1

  公开（公告）日：2007-06-28

  A compound is provided, having the general structure (A): wherein A is an (un)substituted aryl or (un)substituted heteroaryl moiety, G is N, CH, or CR, R is an unsubstituted or substituted lower alkyl, Y is a hydrophobic linking moiety, and L is a substitutent as defined. The compound (A) can be used for treatment of various angiogenic and hematological-associated disorders, such as myeloproliferative disorder in patients who do not respond to kinase-inhibition therapy that comprises administering approved medications.

  提供了一种化合物，其一般结构为(A)：其中A是(未)取代芳基或(未)取代杂环芳基基团，G是N、CH或CR，R是未取代或取代的较低烷基，Y是疏水连接基团，L是定义的取代基。化合物(A)可用于治疗各种与血管生成和血液学有关的疾病，例如在不对包括给予批准药物的激酶抑制治疗做出反应的患者中的骨髓增生性疾病。
• BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE
  申请人：Rice Kenneth D.

  公开号：US20140073628A1

  公开（公告）日：2014-03-13

  The invention is directed to inhibitors of mTOR and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them. The inhibitors are generally of structural formula I and pharmaceutically acceptable salts thereof, wherein the variables are as defined herein.

  本发明涉及mTOR的抑制剂及其药学上可接受的盐或溶剂，以及使用它们的方法。抑制剂通常具有结构式I及其药学上可接受的盐，其中变量如本文所定义。
• Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
  申请人：EXELIXIS, INC.

  公开号：US20140107100A1

  公开（公告）日：2014-04-17

  The invention is directed 10 Compound's of Formula I: and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.

  本发明涉及公式I的化合物，以及其药学上可接受的盐或溶剂化物，以及制备和使用这些化合物的方法。